Doctor of Oncology, Associate Chief Physician **Clinical Expertise:** Diagnosis and treatment of common and complex diseases in medical oncology. Specializes in comprehensive management of thoracic malignancies including lung cancer, pleural mesothelioma, and thymic tumors, encompassing targeted therapy, immunotherapy, and chemotherapy. Diagnosis and management of tumor treatment-related complications, particularly cardiovascular toxicity. Participated in multiple international and domestic multicenter clinical trials of novel drugs in the field of lung cancer. **Professional Affiliations:** Committee Member, International Cardio-Oncology Society (IC-OS); Member, Integrated Cardio-Oncology Society, Chinese Anti-Cancer Association; Member, Lung Cancer Subcommittee, Beijing Cancer Prevention and Treatment Research Association; Member, Immunotherapy Subcommittee, Beijing Cancer Prevention and Treatment Research Association; Member, Science Education Committee, Beijing Cancer Prevention and Treatment Society. **Representative Achievements:** **Principal Investigator of Research Grants:** (1) 2019 Institutional Fund – Merit-Based Project (50,000 RMB, completed). (2) CSCO-Hutchison MediPharma Oncology Research Fund (2021, 80,000 RMB). (3) CSCO-Navigating MET Aberrant Solid Tumor Research Fund Project (2022, 100,000 RMB). (4) 2023 Beijing Hospital Management Center "Cultivation Program" (100,000 RMB). (5) 2025 Peking University Cancer Hospital Research Fund – Interdisciplinary Project (300,000 RMB). (6) 2025 Peking University Cancer Hospital Clinical Research Young Investigator Fund (200,000 RMB). **Publications as First Author or Corresponding Author:** (1) Cao, W., Han, S*., Zhang, P. et al. Immune checkpoint inhibitor-related myocarditis in patients with lung cancer. BMC Cancer 25, 685 (2025). (2) Hong Z, Zhao Y, Pahlavan S, Wang X, Han S*, Wang X, Wang K. iPSC modification strategies to induce immune tolerance. Life Med. 2025, 4(3): lnaf016. (3) Zhihong Yang, Sen Han＃, Ting Zhang, et al. Transcriptomic analysis reveals the messenger RNAs responsible for the progression of alcoholic cirrhosis [J]. Hepatology Communications. 2022, 6(6): 1361-1372. (4) Xu Ma, Sen Han＃, Ying Liu, et al. Pharmacogenetic impact of UGT1A1 polymorphisms on pulmonary neuroendocrine tumors treated with metronomic irinotecan-based chemotherapy in Chinese populations[J]. Journal of Pharmacy and Pharmacology. 2020, 72:1528–1535.